Are you Looking to Buy Olumiant (Barictinib) from PrescriptionPoint.
We don't sell this generic-version medication.
(Top Brand Option)
Olumiant
Olumiant 
Prescription Required | Drug Name | Dosage | Quantity | Price | Buy Now |
|---|---|---|---|---|
| Olumiant | 4mg | 28 | $1501.00 | Add To Cart |
The Olumiant medication listed above is manufactured by Eli Lilly.
Olumiant (baricitinib) is a prescription medication used to treat rheumatoid arthritis, alopecia areata, and COVID-19 in certain patients. The active ingredient is Baricitinib. Olumiant is administered orally. This medication is available in a strength of 4 mg film-coated tablets. The dosage form is film-coated tablets. A generic version of this drug is not available. Olumiant is available by prescription only.
Baricitinib is a Janus kinase (JAK) inhibitor that modulates the signaling of multiple cytokines implicated in the pathophysiology of rheumatoid arthritis. There are no specific alcohol warnings mentioned in the label. It is not recommended during breastfeeding, as the effects on milk production are unknown.
Dose Schedule:
- Rheumatoid Arthritis: 2 mg once daily
- COVID-19: 4 mg once daily for up to 14 days or until hospital discharge
- Dosage may be adjusted based on renal function, hepatic impairment, or certain drug interactions.
Olumiant can be taken with or without food. Strong OAT3 inhibitors (e.g., probenecid) may increase baricitinib exposure.
Mechanism Of Action: Baricitinib inhibits JAK1 and JAK2, modulating the signaling of interleukin-6 and other cytokines.
Overdosage: There is no specific antidote for Olumiant overdose. In case of overdose, monitor the patient for signs and symptoms of adverse reactions.
Pregnancy Warning: Olumiant may cause fetal harm based on animal studies. Not recommended during pregnancy.
Prescribing Info: Dosage adjustments may be necessary for patients with renal impairment, hepatic impairment, or those taking certain medications. Regular monitoring of blood counts and lipids is recommended.
Warning: Olumiant carries boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. It may increase the risk of serious infections, including tuberculosis. Lymphoma and other malignancies have been observed in patients treated with Olumiant.
Remember, Olumiant should only be taken under the supervision of a qualified healthcare professional.
References:
Citations:
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s006lbl.pdf
- https://pi.lilly.com/us/olumiant-us-mg.pdf
- https://pi.lilly.com/ca/olumiant-ca-pm.pdf
- https://pubchem.ncbi.nlm.nih.gov/compound/Baricitinib
- https://www.nps.org.au/assets/medicines/6e146c14-c507-45db-93df-a88500a427d9.pdf
- https://hpr-rps.hres.ca/details.php?drugproductid=4698
- https://dhpp.hpfb-dgpsa.ca/dhpp/resource/103336
- https://en.wikipedia.org/wiki/Baricitinib
- https://pdf.hres.ca/dpd_pm/00066474.PDF
- https://olumiant.lilly.com
Additional information
Scientific Name: |
Barictinib |
|---|---|
Formulation: |
Film Coated Tablet |
Strength(s): |
4mg |
Quantities Available: |
28 |
The information above is provided by third parties to Prescriptionpoint.com for Olumiant (Barictinib). This information is for general purposes only and is not intended to replace a physician's advice. Always consult with your doctor or a qualified health care professional if you need advice on any medical concerns.
